Delivery Order SPE2DB20D2104-SPE2DB25FMELX

Award Date 12/18/24
Potential Completion Date 12/19/24
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMELX
    Delivery Order

This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract, valued at $12,973.37, is for the provision of the specialty medication Skyrizi (risankizumab-rzaa) in a 150 mg/mL pre-filled syringe. The contract has an ultimate completion date of December 19, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. No set-aside requirements are noted for this specific delivery order.

Generated 3/23/25, 12:53 AM